Skip to main content
SpringerLink
Log in

Ifosfamide in advanced pancreatic cancer

A 5-year experience

  • International Satellite Symposium to the 3rd European Conference on Clinical Oncology Stockholm, June 1985 Recent Experience with Ifosfamide/Mesna in Solid Tumor
  • Ifosfamide, Advanced Pancreatic Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Ifosfamide was studied in advanced pancreatic tumor at the National Cancer Institute, Cairo. Over five years, 25 patients received a daily dose of 1.8 g ifosfamide for five days, courses reported every 21 days. Complete remission was achieved in 1 patient and partial remission in 14 patients, an overall result of 60%, average duration of response being 12+ months. Mesna was used for uroprotection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Carter SK, Comis RL (1975) The integration of chemotherapy into a combined modality approach for cancer treatment: VI. Pancreatic adenocarcinoma. Cancer Treat Rev 2:193–214

    Google Scholar 

  2. Inamasu M, McCracken J, Legha S, Chen T, Stephens R, Bukowski R, O'Bryan N, Oishi N, Coltman C (1982) A phase II evaluation ofm-amsa in advanced gastric and pancreatic carcinoma: a SWOG study. Proc Am Soc Clin Oncol 1:100

    Google Scholar 

  3. Hoefer-Janker H, Scheef W, Günther V, et al. (1975) Results obtained with fractionated ifosfamide massive dose treatment in malignant disease. Asta-Werke, Bielefeld AG

    Google Scholar 

  4. Klapdor R, Lehmann U, Kloppel G, Schreiber HW, Greten J (1982) Palliative treatment of pancreatic carcinoma with 5-FU + BCNU and FAM: a prospective randomized study. Digestion 25:43

    Google Scholar 

  5. Oster MW, Theologides A, Cooper MR, Rafla S, Hutchinson JL, Holland JH, Anbar D, Perry MC (1982) Fluorouracil + adriamycin + mitomycin (FAM) in advanced pancreatic cancer. Proc Am Soc Clin Oncol 1:90

    Google Scholar 

  6. Stroehlein JR, Bedikian AY, Karlin DA, Korinek JD, Bodey GP (1982) Phase II evaluation of DHAD, for gastric and pancreatic cancer. Proc Am Soc Clin Oncol 1:94

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, National Cancer Institute, Cairo, Egypt

    Nazli Gad-El-Mawla

Authors
  1. Nazli Gad-El-Mawla
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gad-El-Mawla, N. Ifosfamide in advanced pancreatic cancer. Cancer Chemother. Pharmacol. 18 (Suppl 2), S55–S56 (1986). https://doi.org/10.1007/BF00647453

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00647453

Keywords

Search

Navigation